Issue 1, 2012

A self-immolative dendritic glucuronide prodrug of doxorubicin

Abstract

The first self-immolative dendritic glucuronide prodrug of doxorubicin was studied with the aim to target β-glucuronidase overexpressed in the microenvironment of numerous tumors. This compound includes a chemical amplifier programmed to release two molecules of doxorubicin after a single enzymatic activation step. Upon β-glucuronidase activation, the dendritic prodrug was twice more toxic than its monomeric counterpart against H661 lung cancer cells.

Graphical abstract: A self-immolative dendritic glucuronide prodrug of doxorubicin

Supplementary files

Article information

Article type
Concise Article
Submitted
29 Jul 2011
Accepted
21 Sep 2011
First published
19 Oct 2011

Med. Chem. Commun., 2012,3, 68-70

A self-immolative dendritic glucuronide prodrug of doxorubicin

M. Grinda, J. Clarhaut, B. Renoux, I. Tranoy-Opalinski and S. Papot, Med. Chem. Commun., 2012, 3, 68 DOI: 10.1039/C1MD00193K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements